GRCL News and Press, Gracell Biotechnologies Inc. From 12/10/22

Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate PR Newswire BCMA/CD19 dual-targeting FasTCAR-T GC012F data from ongoing clinical trial presented at 64 th American S...

Chinese biotech Gracell Biotechnologies ( NASDAQ: GRCL ) traded higher for the second straight session on Thursday after H.C. Wainwright launched its coverage with a Buy rating, noting a possible acceptance of a clinical trial application the company intends to file in the U.S. later this...

Gracell Biotechnologies Wins 2022 Fierce Life Sciences Innovation Award PR Newswire FasTCAR next-day manufacturing autologous CAR-T platform recognized with prestigious biotech innovation award SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China , ...

Gracell Biotechnologies Inc. (GRCL) Q3 2022 Results Earnings Conference Call November 14, 2022, 08:00 AM ET Company Participants Kevin Yili Xie - Chief Financial Officer William Wei Cao - Founder, Chairman, and Chief Executive Officer Wendy Li - Chief Medical Off...

Gracell Biotechnologies press release ( NASDAQ: GRCL ): Q3 GAAP EPS of -$0.07 beats by $0.01 . As of September 30, 2022, the Company had RMB1,629.6 million (US$229.1 million) in cash and cash equivalents and short-term investments. For further details see: Gr...

On track to submit IND filings in U.S. and China for GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) in the fourth quarter 2022 First clinical data from ongoing investigator-initiated trial (IIT) evaluating GC012F in newly-diagnosed multiple myeloma (NDMM...

Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed M...

Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022 PR Newswire SAN DIEGO, Calif. , and SUZHOU and SHANGHAI, China , Oct. 31, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a...

Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences PR Newswire SAN DIEGO, Calif. , and SUZHOU and SHANGHAI, China , Oct. 24, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-...

Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia PR Newswire C linical trial assessing allogeneic, HLA-matched, donor-derived all...